BMC Pulmonary Medicine最新文献

{"title":"Role of NAT10-mediated ac⁴C acetylation of ENO1 mRNA in glycolysis and apoptosis in non-small cell lung cancer cells.","authors":"Yanqing Yuan, Na Li, Jingui Zhu, Chun Shao, Xiangbo Zeng, Daijiao Yi","doi":"10.1186/s12890-024-03463-2","DOIUrl":"10.1186/s12890-024-03463-2","url":null,"abstract":"<p><strong>Background: </strong>Abnormal expression of N-acetyltransferase 10 (NAT10) has been shown to promote the progression of various tumors, including non-small cell lung cancer (NSCLC). This study was designed to investigate the role of NAT10 in NSCLC and the underlying mechanism.</p><p><strong>Methods: </strong>Reverse transcription-quantitative polymerase chain reaction and Western blot were used to analyze the levels of NAT10 in NSCLC cell lines. The cell viability, proliferation, and apoptosis of A549 and PC9 cell lines were detected by cell counting kit-8, colony formation, and flow cytometry. N4-acetylcytidine (ac⁴C)-RNA immunoprecipitation assay was performed to detect the level of ac⁴C of α-enolase (ENO1) mRNA in A549 and PC9 cell lines. The relationship between NAT10 and ENO1 was performed by dual-luciferase reporter assay.</p><p><strong>Results: </strong>NAT10 was increased in NSCLC cell lines. The ac⁴C level of ENO1 mRNA in A549 and PC9 cell lines was downregulated after NAT10 inhibition. Knockdown of NAT10 inhibited cell viability and glycolysis and promoted cell apoptosis in A549 and PC9 cell lines, and the results were reversed after ENO1 overexpressing.</p><p><strong>Conclusions: </strong>NAT10 regulated glycolysis and apoptosis in NSCLC via ac⁴C acetylating ENO1, which might provide new ideas for the clinical treatment of NSCLC.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"75"},"PeriodicalIF":2.6,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11827380/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asthma control after recovery from mild to moderate COVID-19: from Omicron BA.2 to XBB- from a cohort in a university hospital in Hong Kong.","authors":"Wang Chun Kwok, Chung Ki Tsui, Terence Chi Chun Tam, David Chi Leung Lam, Mary Sau Man Ip, James Chung Man Ho","doi":"10.1186/s12890-025-03543-x","DOIUrl":"10.1186/s12890-025-03543-x","url":null,"abstract":"<p><strong>Background: </strong>At the time of Omicron BA.2 outbreak, it was shown that mild to moderate COVID-19 was associated with worsening of asthma control after recovery. Whether the same phenomenon was also observed at a later phase of COVID-19 pandemic by other variants have not been reported.</p><p><strong>Methods: </strong>We conducted a follow-up study on patients with asthma who received clinical care in Queen Mary Hospital. The patients were first recruited in the study entitled \"Worsening of asthma control after recovery from mild to moderate COVID-19 in patients from Hong Kong\". The primary outcome was the asthma control test (ACT) score difference among the patients who never had COVID-19 (no COVID-19 group), patients who had COVID-19 diagnosed in the initial study (past COVID-19 group) and patients who had COVID-19 diagnosed in the follow-up period (new COVID-19 group) of the current study.</p><p><strong>Results: </strong>189 patients were included. The change of ACT score from the last visit in the previous study to the last follow-up visit in current study was - 0.34 ± 3.7 in the no COVID-19 group, -0.0 ± 5.0 in the past COVID-19 group and - 0.17 ± 4.5 in the new COVID-19 group (p = 0.94). There were 10 (24.4%), 24 (25.5%) and 12 (22.2%) patients in the no COVID-19, past COVID-19 and new COVID-19 group who had worsening of asthma control by an increase in ACT score ≥ 3 from the last visit in the previous study to the last follow-up visit in current study (p = 0.90).</p><p><strong>Conclusion: </strong>Patients who had COVID-19 in 2023 with Omicron XBB as the dominant strain did not have worsening of asthma control seen in previous study done in 2022 with Omicron BA.2 as the circulating strain. Patients who had worsening of asthma control after COVID-19 in 2022 had subsequent improvement of asthma control with longer follow-up interval.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"74"},"PeriodicalIF":2.6,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11816497/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143398105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A middle-aged man with dyspnea and hoarseness: an unusual case of vocal cord paralysis.","authors":"Seyedeh Nadia Tabatabaeifar, Mahsa Ahmadpour, Mohammad Javad Fallahi","doi":"10.1186/s12890-025-03546-8","DOIUrl":"10.1186/s12890-025-03546-8","url":null,"abstract":"<p><strong>Background: </strong>Pleuroparenchymal fibroelastosis (PPFE) is a rare and distinct form of Interstitial lung disease predominantly affecting the upper lung zones. It is characterized by fibrotic thickening of the visceral pleura and adjacent subpleural parenchyma. While common complications include spontaneous pneumothorax and pneumomediastinum, vocal cord paralysis (VCP) or paresis has been increasingly recognized as a potential manifestation in recent reports.</p><p><strong>Case presentation: </strong>We present a 49-year-old man presenting with progressive dyspnea, hoarseness, and left-sided vocal cord paralysis. Imaging studies revealed upper lobe-dominant fibrotic changes associated with significant pleural thickening consistent with PPFE. A comprehensive evaluation ruled out secondary causes of PPFE and other potential etiologies of VCP. Despite supportive management, the patient's VCP persisted, likely due to architectural distortion of the lung affecting the recurrent laryngeal nerve pathway.</p><p><strong>Conclusions: </strong>This case adds to the limited but growing body of literature on the association between PPFE and VCP. Understanding this rare complication is crucial for early recognition and appropriate management, as it highlights the diverse clinical manifestations of PPFE and its impact on patient outcomes.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"73"},"PeriodicalIF":2.6,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11816999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143398169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipid-lowering drug targets associated with risk of respiratory disease: a Mendelian randomization study.","authors":"Zhipeng Gong, Dongsheng Wu, Yin Ku, Congyao Zou, Lin Qiu, Xiaohu Hao, Lunxu Liu","doi":"10.1186/s12890-025-03527-x","DOIUrl":"10.1186/s12890-025-03527-x","url":null,"abstract":"<p><strong>Background: </strong>Observational studies have identified a possible connection between lipid-lowering medications and respiratory illnesses. However, it remains unclear whether lipid-lowering drugs is causative for respiratory diseases, and we aimed to answer this question.</p><p><strong>Methods: </strong>We performed Mendelian randomization (MR) analyses by integrating data from genome-wide association studies (GWAS). Three statistical approaches were employed for MR analysis: inverse variance weighting (IVW), MR-Egger, and weighted median. The purpose was to evaluate the causal relationships between 10 drug targets that lower lipid levels and the likelihood of developing 7 respiratory diseases. Additional sensitivity analyses were conducted to ensure the robustness and validity of the results.</p><p><strong>Results: </strong>After adjusting for multiple testing, our MR analysis identified APOB (odd ratios [OR]: 0.86; 95% confidence interval [CI]: 0.77 to 0.97; P_IVW = 0.01) and PCSK9 (OR: 0.84; 95% CI: 0.72 to 0.97; P_IVW = 0.02) as significant risk targets for asthma. Additionally, LDLR was found to be a significant risk target for chronic obstructive pulmonary disease (OR: 0.81; 95% CI: 0.67 to 0.98; P_IVW = 0.03). The sensitivity analysis validated no proof of heterogeneity or pleiotropy amongst the mentioned results.</p><p><strong>Conclusions: </strong>Our findings suggest a likely causal relationship between respiratory diseases and lipid-lowering drug targets. Further mechanistic and clinical research is needed to confirm and validate these findings.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"71"},"PeriodicalIF":2.6,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11817876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143398238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and genetic analysis of a patient with diffuse pulmonary lymphangiomatosis: a case report and literature review.","authors":"Yu-Xuan Feng, Tong-Sheng Wang, Shuai Zhang, Wen-Qing Xu, Min Liu, Yi-Min Mao, Ying Nong","doi":"10.1186/s12890-025-03544-w","DOIUrl":"10.1186/s12890-025-03544-w","url":null,"abstract":"<p><strong>Background: </strong>Diffuse pulmonary lymphangiomatosis (DPL) is a rare pulmonary disorder, which affects the lymphatic channels from the mediastinum to the pleura. DPL is often misdiagnosed or missed due to the lack of clear specificity and definitive medical therapies. In most cases, the disease progresses to chronic morbidity or even death.</p><p><strong>Case presentation: </strong>Here, we have reported a case of DPL in a 17-year-old boy who presented with hemoptysis and progressive breathlessness. The diagnosis was confirmed based on the typical imaging features observed through high-resolution computed tomography, chest magnetic resonance imaging, and lymphangiography. Furthermore, we have presented the genetic characteristics of the patient and his parents and discovered the following heterozygous variants of BCL6: NM_001706: exon5: c. A463G (p.M155V) and ATM: NM_000051: exon3: c.A107G (p.D36G). The patient underwent treatment with sirolimus for 2 months; his clinical symptoms disappeared completely, and the mediastinum soft mass shrank dramatically.</p><p><strong>Conclusions: </strong>Early diagnosis of DPL is challenging for clinicians, and imaging plays an important role in determining the location and severity of the disease. The gene mutation detected in this study may facilitate the pathogenesis of DPL. Sirolimus can prevent further disease progression in the short term, which may be an effective and safe therapeutic alternative for treating DPL.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"72"},"PeriodicalIF":2.6,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11817988/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143398133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of the pulmonary fibrosis, pulmonary vascular resistance, six minute walk distance, B-type natriuretic peptide, age (PVD-B65) risk score for patients with chronic lung disease and pulmonary hypertension.","authors":"Shameek Gayen, Jay Pescatore, Matthew Bittner, Mario Naranjo, Gerard J Criner, Sheila Weaver","doi":"10.1186/s12890-025-03538-8","DOIUrl":"10.1186/s12890-025-03538-8","url":null,"abstract":"<p><strong>Background: </strong>Pulmonary hypertension (PH) confers increased mortality in patients with chronic lung disease, yet there remains a lack of validated risk assessment tools to prognosticate these patients. We aimed to create a risk assessment tool to stratify patients with chronic lung disease and PH by risk of one-year mortality from time of PH diagnosis.</p><p><strong>Methods: </strong>This was a retrospective cohort study of patients with chronic lung disease and PH. We identified predictors of one-year mortality via multivariable Cox regression and assigned point values to the identified predictors based on their hazard ratios to comprise the risk score. Patients were stratified into low, intermediate, and high-risk based on total scores. Kaplan-Meier survival analysis comparing the stratified groups was performed. Internal statistical validation was performed via Cox regression with bootstrapping.</p><p><strong>Results: </strong>The identified predictors of one-year mortality that comprised our risk assessment tool were pulmonary fibrosis without emphysema, pulmonary vascular resistance > 5 WU, six-minute walk distance < 150 m, BNP > 200 pg/mL, and age > 65 years (PVD-B65). Once patients were stratified into the three risk groups, Kaplan-Meier survival analysis demonstrated significant differences in one-year survival between the subgroups (logrank p = 0.002). The risk assessment model demonstrated internal validation via bootstrapping (p < 0.05).</p><p><strong>Conclusion: </strong>The PVD-B65 risk assessment tool is a novel, internally validated one-year mortality risk calculator for patients with chronic lung disease and PH that encompasses factors related to pulmonary parenchymal and vascular remodeling. It may help risk stratify and guide therapeutic interventions in patients with chronic lung disease and PH.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"69"},"PeriodicalIF":2.6,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11807298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143373686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unsupervised machine learning clustering approach for hospitalized COVID-19 pneumonia patients.","authors":"Nuttinan Nalinthasnai, Ratchainant Thammasudjarit, Tanapat Tassaneyasin, Dararat Eksombatchai, Somnuek Sungkanuparph, Viboon Boonsarngsuk, Yuda Sutherasan, Detajin Junhasavasdikul, Pongdhep Theerawit, Tananchai Petnak","doi":"10.1186/s12890-025-03536-w","DOIUrl":"10.1186/s12890-025-03536-w","url":null,"abstract":"<p><strong>Background: </strong>Identification of distinct clinical phenotypes of diseases can guide personalized treatment. This study aimed to classify hospitalized COVID-19 pneumonia subgroups using an unsupervised machine learning approach.</p><p><strong>Methods: </strong>We included hospitalized COVID-19 pneumonia patients from July to September 2021. K-means clustering, an unsupervised machine learning method, was performed to identify clinical phenotypes based on clinical and laboratory variables collected within 24 hours of admission. Variables were normalized before clustering to ensure equal contribution to the analysis. The optimal number of clusters was determined using the elbow method and Silhouette scores. Cox proportional hazard models were used to compare the risk of intubation and 90-day mortality across the identified clusters.</p><p><strong>Results: </strong>Three clinically distinct clusters were identified among 538 hospitalized COVID-19 pneumonia patients. Cluster 1 (N = 27) consisted predominantly of males and showed significantly elevated serum liver enzymes and LDH levels. Cluster 2 (N = 370) was characterized by lower chest x-ray scores and higher serum albumin levels. Cluster 3 (N = 141) was characterized by older age, diabetes mellitus, higher chest x-ray scores, more severe vital signs, higher creatinine levels, lower hemoglobin levels, lower lymphocyte counts, higher C-reactive protein, higher D-dimer, and higher LDH levels. When compared to cluster 2, cluster 3 was significantly associated with increased risk of 90-day mortality (HR, 6.24; 95% CI, 2.42-16.09) and intubation (HR, 5.26; 95% CI 2.37-11.72). In contrast, cluster 1 had a 100% survival rate with a non-significant increase in intubation risk compared to cluster 2 (HR, 1.40, 95% CI, 0.18-11.04).</p><p><strong>Conclusions: </strong>We identified three distinct clinical phenotypes of COVID-19 pneumonia patients, with cluster 3 associated with an increased risk of respiratory failure and mortality. These findings may guide tailored clinical management strategies.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"70"},"PeriodicalIF":2.6,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11807335/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143373644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Respiratory abnormalities in sarcoidosis: physiopathology and early diagnosis using oscillometry combined with respiratory modeling.","authors":"Bruno Falcão Oliveira, Caroline Oliveira Ribeiro, Cíntia Moraes de Sá Sousa, Mariana Carneiro Lopes, Agnaldo José Lopes, Pedro Lopes de Melo","doi":"10.1186/s12890-025-03510-6","DOIUrl":"10.1186/s12890-025-03510-6","url":null,"abstract":"<p><strong>Background: </strong>Sarcoidosis is a multisystemic syndrome of uncertain etiology with abnormal respiratory findings in approximately 90% of cases. Spirometry is the most common lung function test used for assessing lung function in diagnosis and monitoring pulmonary health. Respiratory oscillometry allows a simple alternative for the analysis of respiratory abnormalities. Integer-order and fractional-order modeling have increasingly been used to interpret measurements obtained from oscillometry, offering a detailed description of the respiratory system. In this study, we aimed to enhance our understanding of the pathophysiological changes in sarcoidosis and assess the diagnostic accuracy of these models.</p><p><strong>Methods: </strong>This observational study includes 25 controls and 50 individuals with sarcoidosis divided into normal to spirometry (SNS) and abnormal spirometry (SAS). The diagnostic accuracy was evaluated by investigating the area under the receiver operating characteristic curve (AUC).</p><p><strong>Results: </strong>The integer-order model showed significant airway and total resistance increases in the SNS and SAS groups. There was a reduction in compliance and an increase in peripheral resistance in the SAS group (p < 0.001). The fractional-order model showed increased energy dissipation and hysteresivity in the SNS and SAS groups. Correlation analysis revealed significant associations among model and spirometric parameters, where the strongest associations were between total resistance and FEV₁ (r: -0.600, p = 0.0001). The diagnostic accuracy analysis showed that total resistance and hysteresivity were the best parameters, reaching an AUC = 0.986 and 0.938 in the SNS and SAS groups, respectively.</p><p><strong>Conclusion: </strong>The studied models provided a deeper understanding of pulmonary mechanical changes in sarcoidosis. The results suggest that parameters obtained through the studied models enhance evaluation and enable better management of these patients. Specifically, total resistance and hysteresivity parameters demonstrated diagnostic potential, which may be beneficial for the early identification of individuals with sarcoidosis, even when spirometry results are within normal ranges.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"68"},"PeriodicalIF":2.6,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11806852/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143370376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tolerability and efficacy of Mycobacterium avium complex pulmonary disease treatment in elderly patients.","authors":"Kyota Shinfuku, Hiromichi Hara, Keitaro Okuda, Hanae Miyagawa, Naoki Takasaka, Takeo Ishikawa, Jun Araya","doi":"10.1186/s12890-025-03504-4","DOIUrl":"10.1186/s12890-025-03504-4","url":null,"abstract":"<p><strong>Background: </strong>Mycobacterium avium complex pulmonary disease (MAC-PD) is considered to be increasing worldwide. In Japan, the number of elderly MAC-PD patients requiring treatment is also expected to increase due to the aging society. However, reduced organ function in elderly patients makes it often difficult to continue or complete multidrug treatment due to adverse drug reactions (ADRs). Therefore, this study aimed to identify clinical factors associated with treatment tolerability, efficacy, and ADRs in elderly MAC-PD patients.</p><p><strong>Methods: </strong>We retrospectively reviewed the medical records of 102 patients with MAC-PD aged ≥ 75 years between January 2014 and March 2023. Forty-six patients were treated with multidrug regimens (treatment group), and 56 were observed without treatment (observation group). The treatment group was divided into the treatment continuation group (n = 28) who were treated without interruption for ≥ 12 months, and the treatment interruption group (n = 18). A comparative study was conducted in each group to examine tolerability, efficacy, and ADRs.</p><p><strong>Results: </strong>A two-drug regimen of ethambutol (EB) and macrolides without rifampicin (RFP) was associated with treatment continuation (p = 0.026). The treatment continuation group was superior to the observation group regarding symptoms change, sputum conversion rate, and chest computed tomography scores. The most common ADRs were gastrointestinal disorders, which may be related to RFP. Treatment efficacy of the two-drug regimen was non-inferior, and no cases of macrolide resistance were observed.</p><p><strong>Conclusions: </strong>The two-drug regimen of EB and macrolide without RFP may be a tolerable and effective treatment for elderly MAC-PD patients.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"67"},"PeriodicalIF":2.6,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11806669/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143370377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case report of confirmed difficult pulmonary tuberculosis based on the hybrid capture-based tNGS method.","authors":"Weiqian Chen, Huimin Chen, Ze Liu, Xinle Chi, Yaomeng Chen, Huan Ye, Wenjie Huang, Chenlei Cao, Wei Weng","doi":"10.1186/s12890-025-03539-7","DOIUrl":"10.1186/s12890-025-03539-7","url":null,"abstract":"<p><strong>Background: </strong>Early diagnosis of pulmonary tuberculosis can greatly reduce the harm caused by the disease. However, traditional diagnostic methods have various shortcomings in diagnosing pulmonary tuberculosis. Currently, with the increasing popularity, iteration, and decreasing costs of Next-generation sequencing (NGS) testing technology, NGS is being more widely applied in the diagnosis of pulmonary tuberculosis.</p><p><strong>Case presentation: </strong>A 29-year-old male presented with \"fever accompanied by cough for more than 20 days.\" Multiple chest CT scans revealed progressive enlargement of the right hilar lymph nodes and thickening of the interlobular septa in the right upper lobe. Routine testing of bronchoalveolar lavage fluid, search for tuberculosis bacilli, bacterial and fungal cultures, X-pert MTB/RIF, and multiplex PCR-based targeted Next-generation sequencing (mp-tNGS) results were all inconclusive. Finally, bronchoalveolar lavage fluid was sent for hybrid capture-based targeted Next-generation sequencing (hc-tNGS) testing, and special staining of the enlarged lymph nodes confirmed the diagnosis of pulmonary tuberculosis.</p><p><strong>Conclusion: </strong>The hc-tNGS has significant value in diagnosing pulmonary tuberculosis, especially in cases that are difficult to detect with other methods. In the future, this could gradually become a routine diagnostic method for pulmonary tuberculosis, enhancing the accuracy of early diagnosis.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"64"},"PeriodicalIF":2.6,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11800540/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143363657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}